
Selecxin
Innovative immunotherapeutics development through unique technology and active research collaboration.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 | round | |
investor | €0.0 | round | |
* | KRW33.0b | Series B | |
Total Funding | 000k |
Related Content
Selecxine is a biotechnology company focused on the development of effective immunotherapeutics to improve the quality of life. The company leverages its unique technology and active research collaborations to create differentiated antibody solutions. Selecxine operates in the biopharmaceutical market, primarily serving healthcare providers and research institutions. The business model revolves around the research and development of novel antibodies, which are then licensed or sold to pharmaceutical companies. Revenue is generated through licensing agreements, research grants, and partnerships with larger pharmaceutical firms.
Keywords: immunotherapeutics, biotechnology, antibody development, healthcare, research collaboration, biopharmaceutical, licensing, pharmaceutical partnerships, epitope mapping, preclinical research.